SENSUS HEALTHCARE INC (SRTS) Fundamental Analysis & Valuation

NASDAQ:SRTS • US81728J1097

Current stock price

4.22 USD
+0.26 (+6.57%)
Last:

This SRTS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SRTS Profitability Analysis

1.1 Basic Checks

  • In the past year SRTS has reported negative net income.
  • In the past year SRTS had a positive cash flow from operations.
  • Of the past 5 years SRTS 4 years were profitable.
  • SRTS had negative operating cash flow in 4 of the past 5 years.
SRTS Yearly Net Income VS EBIT VS OCF VS FCFSRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

1.2 Ratios

  • The Return On Assets of SRTS (-14.55%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -16.05%, SRTS is in the better half of the industry, outperforming 62.43% of the companies in the same industry.
Industry RankSector Rank
ROA -14.55%
ROE -16.05%
ROIC N/A
ROA(3y)-0.99%
ROA(5y)10.51%
ROE(3y)-1.05%
ROE(5y)12.62%
ROIC(3y)N/A
ROIC(5y)N/A
SRTS Yearly ROA, ROE, ROICSRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

1.3 Margins

  • SRTS has a worse Gross Margin (43.18%) than 63.49% of its industry peers.
  • In the last couple of years the Gross Margin of SRTS has declined.
  • The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.42%
GM growth 5Y-4.65%
SRTS Yearly Profit, Operating, Gross MarginsSRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. SRTS Health Analysis

2.1 Basic Checks

  • SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SRTS has about the same amount of shares outstanding.
  • The number of shares outstanding for SRTS remains at a similar level compared to 5 years ago.
  • There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRTS Yearly Shares OutstandingSRTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
SRTS Yearly Total Debt VS Total AssetsSRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • SRTS has an Altman-Z score of 8.87. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 8.87, SRTS belongs to the best of the industry, outperforming 87.30% of the companies in the same industry.
  • SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.87
ROIC/WACCN/A
WACC10.58%
SRTS Yearly LT Debt VS Equity VS FCFSRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 9.72 indicates that SRTS has no problem at all paying its short term obligations.
  • SRTS's Current ratio of 9.72 is amongst the best of the industry. SRTS outperforms 90.48% of its industry peers.
  • SRTS has a Quick Ratio of 6.31. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 6.31, SRTS belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.72
Quick Ratio 6.31
SRTS Yearly Current Assets VS Current LiabilitesSRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SRTS Growth Analysis

3.1 Past

  • The earnings per share for SRTS have decreased strongly by -217.50% in the last year.
  • SRTS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.26%.
  • Measured over the past years, SRTS shows a very strong growth in Revenue. The Revenue has been growing by 23.46% on average per year.
EPS 1Y (TTM)-217.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-311.11%
Revenue 1Y (TTM)-34.26%
Revenue growth 3Y-14.86%
Revenue growth 5Y23.46%
Sales Q2Q%-62.2%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.86% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 23.94% on average over the next years. This is a very strong growth
EPS Next Y38.51%
EPS Next 2Y48.53%
EPS Next 3Y27.34%
EPS Next 5Y29.86%
Revenue Next Year-10.94%
Revenue Next 2Y9.33%
Revenue Next 3Y12.24%
Revenue Next 5Y23.94%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SRTS Yearly Revenue VS EstimatesSRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SRTS Yearly EPS VS EstimatesSRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. SRTS Valuation Analysis

4.1 Price/Earnings Ratio

  • SRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTS Price Earnings VS Forward Price EarningsSRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • 68.78% of the companies in the same industry are more expensive than SRTS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 209.22
EV/EBITDA N/A
SRTS Per share dataSRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SRTS's earnings are expected to grow with 27.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.53%
EPS Next 3Y27.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRTS Dividend Analysis

5.1 Amount

  • SRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRTS Fundamentals: All Metrics, Ratios and Statistics

SENSUS HEALTHCARE INC

NASDAQ:SRTS (3/25/2026, 8:00:01 PM)

4.22

+0.26 (+6.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners29.19%
Inst Owner Change-2.84%
Ins Owners17.85%
Ins Owner Change1.61%
Market Cap69.46M
Revenue(TTM)27.48M
Net Income(TTM)-7.72M
Analysts82.22
Price Target6.8 (61.14%)
Short Float %3.57%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-64.01%
Min EPS beat(2)-166.11%
Max EPS beat(2)38.08%
EPS beat(4)1
Avg EPS beat(4)-253.91%
Min EPS beat(4)-561.36%
Max EPS beat(4)38.08%
EPS beat(8)4
Avg EPS beat(8)51.45%
EPS beat(12)6
Avg EPS beat(12)1.05%
EPS beat(16)7
Avg EPS beat(16)-1.06%
Revenue beat(2)1
Avg Revenue beat(2)-17.53%
Min Revenue beat(2)-41.98%
Max Revenue beat(2)6.91%
Revenue beat(4)2
Avg Revenue beat(4)-11.22%
Min Revenue beat(4)-41.98%
Max Revenue beat(4)13.08%
Revenue beat(8)6
Avg Revenue beat(8)25.42%
Revenue beat(12)7
Avg Revenue beat(12)9.19%
Revenue beat(16)9
Avg Revenue beat(16)11.02%
PT rev (1m)-9.09%
PT rev (3m)-9.09%
EPS NQ rev (1m)-50.01%
EPS NQ rev (3m)-150%
EPS NY rev (1m)-372.22%
EPS NY rev (3m)-2933.3%
Revenue NQ rev (1m)-23.56%
Revenue NQ rev (3m)-35.33%
Revenue NY rev (1m)-22.61%
Revenue NY rev (3m)-31.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.53
P/FCF 209.22
P/OCF 131.56
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)0.02
FCFY0.48%
OCF(TTM)0.03
OCFY0.76%
SpS1.67
BVpS2.92
TBVpS2.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.55%
ROE -16.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.18%
FCFM 1.21%
ROA(3y)-0.99%
ROA(5y)10.51%
ROE(3y)-1.05%
ROE(5y)12.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.42%
GM growth 5Y-4.65%
F-Score5
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 50.78%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.72
Quick Ratio 6.31
Altman-Z 8.87
F-Score5
WACC10.58%
ROIC/WACCN/A
Cap/Depr(3y)83.18%
Cap/Depr(5y)64.17%
Cap/Sales(3y)0.77%
Cap/Sales(5y)0.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-217.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-311.11%
EPS Next Y38.51%
EPS Next 2Y48.53%
EPS Next 3Y27.34%
EPS Next 5Y29.86%
Revenue 1Y (TTM)-34.26%
Revenue growth 3Y-14.86%
Revenue growth 5Y23.46%
Sales Q2Q%-62.2%
Revenue Next Year-10.94%
Revenue Next 2Y9.33%
Revenue Next 3Y12.24%
Revenue Next 5Y23.94%
EBIT growth 1Y-227.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.1%
EBIT Next 3Y28.62%
EBIT Next 5Y-20.08%
FCF growth 1Y129.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y163.54%
OCF growth 3YN/A
OCF growth 5YN/A

SENSUS HEALTHCARE INC / SRTS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SENSUS HEALTHCARE INC (SRTS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to SRTS.


What is the valuation status of SENSUS HEALTHCARE INC (SRTS) stock?

ChartMill assigns a valuation rating of 2 / 10 to SENSUS HEALTHCARE INC (SRTS). This can be considered as Overvalued.


What is the profitability of SRTS stock?

SENSUS HEALTHCARE INC (SRTS) has a profitability rating of 2 / 10.


How financially healthy is SENSUS HEALTHCARE INC?

The financial health rating of SENSUS HEALTHCARE INC (SRTS) is 9 / 10.